Currently, there is no preventative treatment for age-related macular degeneration (AMD), the leading cause of blindness among the elderly in the U.S.. Development of therapeutic interventions will require an understanding of the molecular events associated with the disease. In this proposal, we will test the hypothesis that a subset of proteins will be uniquely altered with AMD and that the progression of AMD will involve an evolution of protein changes that are manifest in clinically distinct features. This research will take an innovative analytical approach by using proteomic technology to identify specific proteins that are altered in the sensory retina and retinal pigment epithelium (RPE) with AMD. Donors selected (ages 65-75) will include those exhibiting either no AMD (control) or retinal features that are indicative of the beginning or later stages of the disease. The following aims will be pursued: (1) Evaluate and classify retinal degeneration in donor eyes. Prior to biochemical analysis, we will evaluate the macular region of donor eyes using the Age-related Eye Disease (AREDS) system. (2) Identify alterations in retinal proteins using proteomic analysis. We will perform proteome analysis to identify proteins in the RPE and sensory retina that have altered expression or contain the oxidative modification, 4-hydroxynonenal. Using donor retinas at clinically defined stages of AMD should aid in distinguishing patterns of protein changes that are associated with the progression of the disease. Identification of proteins that are uniquely altered will help provide valuable insight into the mechanism of AMD.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Small Research Grants (R03)
Project #
1R03EY014176-01A1
Application #
6727783
Study Section
Special Emphasis Panel (ZEY1-VSN (01))
Program Officer
Dudley, Peter A
Project Start
2004-01-01
Project End
2006-11-30
Budget Start
2004-01-01
Budget End
2004-11-30
Support Year
1
Fiscal Year
2004
Total Cost
$148,500
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Olsen, Timothy W (2008) The Minnesota Grading System using fundus autofluorescence of eye bank eyes: a correlation to age-related macular degeneration (an AOS thesis). Trans Am Ophthalmol Soc 106:383-401
Nordgaard, Curtis L; Karunadharma, Pabalu P; Feng, Xiao et al. (2008) Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci 49:2848-55
Decanini, A; Karunadharma, P R; Nordgaard, C L et al. (2008) Human retinal pigment epithelium proteome changes in early diabetes. Diabetologia 51:1051-61
Ethen, Cheryl M; Reilly, Cavan; Feng, Xiao et al. (2007) Age-related macular degeneration and retinal protein modification by 4-hydroxy-2-nonenal. Invest Ophthalmol Vis Sci 48:3469-79
Decanini, Alejandra; Nordgaard, Curtis L; Feng, Xiao et al. (2007) Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol 143:607-15
Ethen, Cheryl M; Hussong, Stacy A; Reilly, Cavan et al. (2007) Transformation of the proteasome with age-related macular degeneration. FEBS Lett 581:885-90
Gregerson, Dale S; Heuss, Neal D; Lew, Kathleen L et al. (2007) Interaction of retinal pigmented epithelial cells and CD4 T cells leads to T-cell anergy. Invest Ophthalmol Vis Sci 48:4654-63
Ferrington, Deborah A; Tran, Tina N; Lew, Kathleen L et al. (2006) Different death stimuli evoke apoptosis via multiple pathways in retinal pigment epithelial cells. Exp Eye Res 83:638-50
Nordgaard, Curtis L; Berg, Kristin M; Kapphahn, Rebecca J et al. (2006) Proteomics of the retinal pigment epithelium reveals altered protein expression at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci 47:815-22
Gregerson, Dale S; Lew, Kathleen L; McPherson, Scott W et al. (2006) RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing. Invest Ophthalmol Vis Sci 47:5385-94

Showing the most recent 10 out of 15 publications